

## Datasheet: BUF04C

**BATCH NUMBER 172006**

<b>Description:</b>	ERYTHROLYSE RED BLOOD CELL LYSING BUFFER (10x)
<b>Name:</b>	RED CELL LYSING BUFFER
<b>Format:</b>	Reagent
<b>Product Type:</b>	Accessory Reagent
<b>Quantity:</b>	500 TESTS/100ml

## Product Details

### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

### Instructions For Use

Bio-Rad ERYTHROLYSE is supplied as a 10X concentration solution which must be diluted 1/10 with distilled water before use.

Bio-Rad ERYTHROLYSE is designed for use in whole blood immunofluorescent staining procedures and is suitable for use with human, rat and mouse blood.

Following staining according to standard procedures ([worksheets](#) available on request), 2ml of diluted ERYTHROLYSE is added to 100ul of whole blood, mixed well and incubated for 10 minutes at room temperature. The tubes should then be centrifuged (400g, 5 minutes), the supernatant decanted and cells washed once in 2ml PBS/1% BSA before analysis by flow cytometry.

### References

1. Clausen, B.H. *et al.* (2008) Interleukin-1beta and tumor necrosis factor-alpha are expressed by different subsets of microglia and macrophages after ischemic stroke in mice. [J. Neuroinflammation. 5:46.](#)
2. Hussein, O.A. *et al.* (2010) Neutrophil CD64 Expression in Inflammatory Autoimmune Diseases: Its Value in Distinguishing Infection from Disease Flare. [Immunol Invest. 39: 699-712.](#)

3. Peart, D.J. *et al.* (2016) Implications of a pre-exercise alkalosis-mediated attenuation of HSP72 on its response to a subsequent bout of exercise. [Amino Acids. 48 \(2\): 499-504.](#)
4. Zarkesh-Esfahani, H. *et al.* (2001) High-dose leptin activates human leukocytes via receptor expression on monocytes. [J Immunol. 167 \(8\): 4593-9.](#)
5. Zhang, Z. *et al.* (2008) FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves. [Exp Neurol. 210 \(2\): 681-90.](#)
6. Zhang Z *et al.* (2012) Valproic acid ameliorates inflammation in experimental autoimmune encephalomyelitis rats. [Neuroscience. 221: 140-50.](#)
7. Zhang, Z.Y. & Schluesener, H.J. (2012) HDAC inhibitor MS-275 attenuates the inflammatory reaction in rat experimental autoimmune prostatitis. [Prostate. 72 \(1\): 90-9.](#)
8. Li, M. *et al.* (2012) Astragaloside IV protects against focal cerebral ischemia/reperfusion injury correlating to suppression of neutrophils adhesion-related molecules. [Neurochem Int. 60 \(5\): 458-65.](#)
9. Villaescusa, A. *et al.* (2012) Immunophenotypic evaluation of working Labrador Retrievers and German Shepherd dogs living in the same environment. [Vet J. 193 \(2\): 602-5.](#)
10. Elgström, E *et al.* (2015) Role of CD8-positive cells in radioimmunotherapy utilizing (177)Lu-mAbs in an immunocompetent rat colon carcinoma model. [EJNMMI Res. 5: 3.](#)
11. García-Sancho M *et al.* (2014) Comparative study of peripheral blood leukocytes in healthy dogs and in dogs with cancer and inflammatory diseases. [J Vet Diagn Invest. 26 \(2\): 282-5.](#)
12. Karayannopoulou, M. *et al.* (2017) Evaluation of blood T-lymphocyte subpopulations involved in host cellular immunity in dogs with mammary cancer. [Vet Immunol Immunopathol. 186: 45-50.](#)
13. Dwivedi, S. *et al.* (2010) Rac1-mediated signaling plays a central role in secretion-dependent platelet aggregation in human blood stimulated by atherosclerotic plaque. [J Transl Med. 8: 128.](#)
14. Grad, E. *et al.* (2019) Monocyte Modulation by Liposomal Alendronate Improves Cardiac Healing in a Rat Model of Myocardial Infarction [Regenerative Engineering and Translational Medicine. 5 \(3\): 280-9.](#)
15. Moreno-Vicente, J. *et al.* (2022) Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments. [J Immunother Cancer. 10\(1\):e003735.](#)
16. Karayannopoulou, M. *et al.* (2022) Effect of anaesthesia on cell-mediated immunity in dogs undergoing mastectomy for mammary cancer [Vet Anaesth Analg. Jan 31 \[Epub ahead of print\].](#)
17. Hussain, K. *et al.* (2022) HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy. [J Exp Clin Cancer Res. 41 \(1\): 131.](#)
18. Elsayed, M.S.A.E. *et al.* (2022) Real-time PCR using atpE, conventional PCR targeting different regions of difference, and flow cytometry for confirmation of *Mycobacterium bovis* in buffaloes and cattle from the Delta area of Egypt. [BMC Microbiol. 22 \(1\): 154.](#)
19. Brynedal, B. *et al.* (2023) Molecular signature of methotrexate response among rheumatoid arthritis patients. [Front Med \(Lausanne\). 10: 1146353.](#)
20. Reus, P. *et al.* (2023) Drug repurposing for the treatment of COVID-19: Targeting

nafamostat to the lungs by a liposomal delivery system. [J Control Release. 364: 654-71.](#)

21. Agbaria, M. *et al.* (2023) Nanoparticles of VAV1 siRNA combined with LL37 peptide for the treatment of pancreatic cancer. [J Control Release. 355: 312-26.](#)

22. Ptacin, J.L. *et al.* (2024) A CD25-biased interleukin-2 for autoimmune therapy engineered via a semi-synthetic organism. [Commun Med \(Lond\). 4 \(1\): 58.](#)

23. Merkulov, E.D. *et al.* (2025) Monocyte and Macrophage in Follicular Liquid: Predictive Markers of Embryo Quality in Women with Obesity and Infertility. [Front Biosci \(Landmark Ed\). 30 \(1\): 26660.](#)

---

<b>Storage</b>	This product is shipped at ambient temperature. The 10X concentrated ERYTHROLYSE should be stored at room temperature and is stable for 1 year. Do not use if any discolouration or precipitation occurs in the ERYTHROLYSE solution. The information regarding the products is believed to be accurate, but the information and products have no warranty or guarantee other than those specified, since the ultimate conditions of use and the variability of the materials are beyond our control. We cannot be responsible for and we do not intend these products or the accompanying information to be used for patent infringement or other such violations.
<b>Guarantee</b>	12 months from date of despatch
<b>Health And Safety Information</b>	Material Safety Datasheet documentation #10212 available at: <a href="https://www.bio-rad-antibodies.com/SDS/BUF04C">https://www.bio-rad-antibodies.com/SDS/BUF04C</a>
<b>Regulatory</b>	For research purposes only

---

**Product inquiries:** [www.bio-rad-antibodies.com/technical-support](http://www.bio-rad-antibodies.com/technical-support)

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](http://bio-rad-antibodies.com/datasheets)  
'M439310:250523'

**Printed on 05 Mar 2026**